Nuvation Bio (NYSE:NUVB – Get Rating)‘s stock had its “outperform” rating restated by investment analysts at Royal Bank of Canada in a report released on Thursday, Benzinga reports. They presently have a $6.00 target price on the stock. Royal Bank of Canada’s price target would indicate a potential upside of 265.85% from the stock’s previous close.
Other research analysts also recently issued reports about the company. Jefferies Financial Group downgraded Nuvation Bio from a “buy” rating to a “hold” rating and cut their price objective for the company from $5.00 to $2.00 in a research note on Friday, January 6th. Wedbush reaffirmed an “outperform” rating and issued a $5.00 price target on shares of Nuvation Bio in a research report on Thursday. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Nuvation Bio currently has a consensus rating of “Moderate Buy” and an average target price of $4.00.
Nuvation Bio Stock Performance
Shares of NUVB stock opened at $1.64 on Thursday. The stock’s 50 day simple moving average is $2.11 and its 200 day simple moving average is $2.12. Nuvation Bio has a twelve month low of $1.55 and a twelve month high of $6.02. The company has a market capitalization of $358.16 million, a price-to-earnings ratio of -3.28 and a beta of 0.66.
Institutional Inflows and Outflows
About Nuvation Bio
Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer.
- Get a free copy of the StockNews.com research report on Nuvation Bio (NUVB)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.